Coreline Soft to Unveil ‘One CT Scan, Multiple Diseases’ Strategy at RSNA 2026
South Korean medical artificial intelligence (AI) company Coreline Soft announced on November 19, 2026, that it will showcase its chest CT-based AI platform, AVIEW, at the Radiological Society of North America's annual meeting, RSNA 2026, scheduled for November 29 through December 3 at McCormick Place in Chicago. The company will exhibit at Booth 5135 in the AI Showcase, located on Level 3 of the…
Coreline Soft, a medical AI company from South Korea, will unveil its "One CT Scan, Multiple Diseases" strategy at the Radiological Society of North America's (RSNA) 2026 annual meeting in Chicago. The company's chest CT-based AI platform, AVIEW, aims to extract quantitative information on various lung and cardiovascular conditions from a single CT examination, extending its clinical value beyond pulmonary nodule detection to include emphysema, COPD, CAC, and ILA.
The company will showcase five products from its AVIEW portfolio, including AVIEW LCS for pulmonary nodule detection, AVIEW Lung Nodule CAD for automated pulmonary nodule detection, AVIEW COPD for quantitative analysis of emphysema and airways, AVIEW CAC for coronary artery calcification measurement, and AVIEW Aorta Metrics for aortic diameter analysis.
AVIEW has received FDA 510(k) clearance for AVIEW Aorta Metrics, bringing the company's total number of FDA clearances to 13, and is currently used at over 500 healthcare institutions across 19 countries, with more than 3.5 million imaging examinations analyzed by the platform.
Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.